A Single-Arm, Open-Label phase 4 study of Nirogacestat in adult premenopausal females with desmoid tumors/aggressive Fibromatosis (DT/AF)

Title

Code

NIR-DT-401

Type

Sperimentale con farmaco

Start Year

2025

Status

In Corso

Principal Investigator

051-6365503

giorgio.frega@ior.it

Frega Giorgio, MD, PhD

Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies

Operational unit that carry out the study

complex unit

Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative

Director

Ibrahim Toni, BSc, MSc, MD, PhD

Go to the details >>

Description

Studio clinico promosso da SpringWorks Therapeutics, Inc.

Documents and Videos attachament

Attachment

Nulla osta alla conduzione dello studio prot. NIR-DT-401

Wednesday 7 January 2026, 16:01

PG0017993_2025_Stampa_unica.pdf

You might also be interested in

Clinical Trial

A Phase 2/3, Randomized, Multicenter Study to Evaluate AL102 in Patients with Progressing Desmoid Tumors

Clinical Trial

Phase study 1/2 to evaluate palbociclib (IBRANCE®) in combination with irinotecan and temozolomide or in combination with topotecan and cyclophosphamide in pediatric patients with recurrent orrefractory solid tumors

IRCCS

ISTITUTO ORTOPEDICO RIZZOLI

A Single-Arm, Open-Label phase 4 study of Nirogacestat in adult premenopausal females with desmoid tumors/aggressive Fibromatosis (DT/AF)

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in

Sito Web Istituto Ortopedico Rizzoli

A Single-Arm, Open-Label phase 4 study of Nirogacestat in adult premenopausal females with desmoid tumors/aggressive Fibromatosis (DT/AF)

Principal Investigator

Operational unit that carry out the study

Description

Documents and Videos attachament

You might also be interested in